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68 Poster Session-ICD34(1) cell dose received (Table 1). Our data expand on previous
work in this area by including data in patients receiving chemother-
apy, thalidomide and bortezomib based inductions. Findings suggest
pre-mobilization marrow plasmacytosis may be a practical, effective
test to determine chances of mobilization success in patients with
prior lenalidomide exposure.
Effects of induction regimen on stem cell mobilization
Type of InductionChemotherapy Thalidomide Lenalidomide Bortezomib vp-
aluePre-mobilization
bone marrow:plasmacytosis,
successfully
mobilized (%)22 14 5 12 0.001plasmacytosis,
failed
mobilization
(%)39 21 23 0.004Apheresis
sessions
(median)2 2 3 2 0.008CD34(1) stem
cell
collection:Day 1 9.9 7.4 3.6 6.1 0.004Total 18 11 8 8 0.0001Engraftment
kinetics:ANC
. 500/uL
(days)9 10 11 10.5 0.003182
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ASCT has demonstrated to prolong the survival in Multiple Mye-
loma (MM) patients, but the benefit of this therapy and impact of co-
morbidities for elderly patients has not been well established. We
retrospectively analyzed MM patients aged $ 65 years who under-
went ASCT from 2001 to 2006. We examined a series of clinical pa-
rameters [e.g. age, gender, stage at diagnosis, time from diagnosis to
transplant (TDT), lines of chemotherapy before transplant, response
to first-line therapy, conditioning regimens, incidence and type of
non-hematological toxicities (NHT), and comorbidity] and clinical
outcomes [e.g. time to neutrophils and platelets engraftment, length
of hospital stay (LOS), progression-free survival (PFS), and overall
survival (OS)]. PFS and OS were calculated from the time of trans-
plant to the time of event occurrence. One-hundred and ten patients
(45 F, 65 M), median age 68 (65–77), were eligible. Two thirds had
Durie-Salmon stage III, 31% received more than 1 line of therapy,
and 27% were refractory to first-line therapy. The median TDT
was 8.8 months (2–208). The mean scores for Charlson comorbidity
index, cumulative illness rating scale for geriatrics, and Hemopoietic
Stem cell Transplantation Comorbidity Index, retrospectively calcu-
lated at time of transplant, were 0.6 (0–6), 5 (0–12), and 2 (0–7), re-
spectively. Conditioning regimens were melphalan alone (63%) or
melphalan plus other drugs (37%). The median LOS was 19 days
(0–60). Thirty-seven percent of patients did not develop any grade
4 NHT; the most common grade 4 NHT were infection, mucositis,
and supraventricular arrhythmias. The median number of days to
neutrophils .0.5  109/L and to platelets .20  109/L was 12 (6–40) and 13 (6–187), respectively. TRM at day 100 was 4.5%.Median
PFS and OS were 14.3 (12.2–20.3) and 36.7 months (28.2–45.4), re-
spectively. Multivariate analysis showed male was a significant factor
for time to neutrophil engraftment (HR5 0.64; 95%CI: 0.41–0.99).
Older age (HR 5 0.92; 95% CI: 0.85–0.99) and more toxicities
(HR 5 0.49; 95% CI: 0.38–0.63) were significant predictors for in-
creasing LOS. Longer TDT was significant (HR 5 1.02; 95% CI:
1.00–1.03) for decreasing LOS. No factor was found to be signifi-
cantly predictive for PFS and OS. Comorbidity did not predict PFS
and OS at univariate level. ASCT in MM patients aged $ 65 years
is associated with low peritransplant mortality and manageable
toxicity making it a feasible option for this patient population.183
COMBINATION OF IFN-/GM-CSF AS MAINTENANCE THERAPY FORMULTI-
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TATION (ASCT): RESULTS OF A PROSPECTIVE PHASE II STUDY
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Several studies have shown that maintenance therapy with IFN-
a after ASCT prolongs response duration and may improve survival.
In our experience, up to 30% of the patients are unable to take IFN-
a because of either slow hematopoietic recovery after ASCTor IFN-
induced pancytopenia. In this study, we combined GM-CSF with
IFN-a in order to improve IFN tolerance in post-ASCT myeloma
patients. Primary aims were to evaluate toxicity, long term side ef-
fects, and effectiveness of this combination maintenance therapy.
The treatment (4  106 units of IFN-a and 125 mg/m2 of GM-
CSF) schedule was three times a week (M, W, F) for twelve months.
After that, patients would continue IFN-a at the discretion of the
treating physician. Between January 2003 and June 2007, 27 patients
were enrolled after signing informed consents within 120 days of
ASCT, and four of them had tandem ASCT. Patients with progres-
sive myeloma were excluded from study. One enrolled patient was
excluded from analysis for not taking the drugs. Only one patient dis-
continued treatment due to moderate pancytopenia and two devel-
oped skin rashes/cellulitis related to GM-CSF injections. Seven
others were taken off study due to persistent IFN-related flu-like
symptoms and/or increase in liver enzymes. Median length of treat-
ment with the combination was 11.5 months. Seven patients contin-
ued IFN-a beyond one year, four of whom are still taking it. With
a median follow-up of 44.5 months (n5 26), an intent -to-traet anal-
ysis reveals overall survival (OS) and progression-free survival (PFS)
of 51 and 45 months, respectively. Eleven patients (42%) have re-
mained in VGPR/CR since ASCT. These results were compared
to a historical group of patients (n 5 25) who had a median of 8
months IFN only treatment with PFS of 22 months. In conclusion,
our results demonstrate the effectiveness of GM-CSF in ameliorat-
ing the IFN-induced myelotoxicity and achieving better PFS.184
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Background: Allogeneic hematopoietic stem cell transplantation
(allo SCT) is a potentially curative approach in patients withmultiple
myeloma (MM). The potential benefit is offset by a higher risk of
transplant-related mortality (TRM), graft-vs-host disease (GVHD)
and opportunistic infections. A number of factors including better
supportive care, antimicrobial agents, improvement in HLA typing
and reduced intensity conditioning (RIC) regimens have resulted in
a lower risk of TRM. We evaluated if there was an improvement in
the outcome of patients who received allo SCT forMMafter January
1, 2000 compared to patients who received allo SCTbefore that date.
Methods: 101 patients underwent allo SCT at UT-MDACC be-
tween 11/1985 and 1/2007, with 40 patients undergoing allo SCT
before January 1, 2000 (group A) and 61 after that date (group B).
Median age at allo SCT in Group A and B was 42 and 48 years,
